The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Bridge to Life sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Bridge to Life develops preservation solutions and technologies while providing quality services to organ procurement organizations and transplant centers. It offers storage and perfusion products, including Belzer UW (cold storage solution), Belzer MPS (UW machine perfusion solution), EasiSlush (sodium chloride solution for sterile slush preparation), French-sized cannulas and tubing; and machine perfusion products including VitaSmart, EVOSS, LifeCradle heart preservation system which are used to preserve, store, and monitor perfusion progress. The company sells its products worldwide. Bridge to Life is headquartered in Northbrook, Illinois, the US.
The key metrics of Bridge to Life related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Bridge to Life is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Bridge to Life.
For a detailed understanding of the performance of Bridge to Life, buy the report here.